Neurogene Strengthens Leadership with New CCO and Board Member
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Businesswire
Image: Businesswire
Neurogene Inc., a clinical-stage biotechnology company based in New York, has appointed Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. Shafer will lead the commercial strategy for the NGN-401 gene therapy aimed at treating Rett syndrome, while Mikail will contribute her extensive expertise in corporate development.
- 01Christy Shafer appointed as Chief Commercial Officer.
- 02Christine Mikail joins the Board of Directors.
- 03Shafer will oversee the launch strategy for NGN-401 gene therapy for Rett syndrome.
- 04Mikail brings significant strategic and operational experience to the Board.
- 05Neurogene focuses on genetic medicines for rare neurological diseases.
Advertisement
In-Article Ad
Neurogene Inc. (NASDAQ: NGNE), a biotechnology company based in New York, has announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. Shafer, who has over 20 years of experience in the industry, will be responsible for leading the commercial strategy and launch readiness for NGN-401, a gene therapy targeting Rett syndrome. She previously held senior roles at Avidity Biosciences and Marinus Pharmaceuticals, where she successfully launched therapies for rare neurological diseases. Mikail, who is currently the President and CFO of Neurogene, will enhance the Board's strategic and operational leadership as the company advances its key priorities. Her expertise in strategic transactions and corporate development is expected to support Neurogene's long-term growth objectives. Both appointments come at a crucial time as Neurogene prepares for the potential commercialization of NGN-401, which represents a significant opportunity to improve outcomes for patients suffering from devastating neurological conditions.
Advertisement
In-Article Ad
The appointments of Shafer and Mikail are expected to enhance Neurogene's capabilities in launching NGN-401, potentially benefiting patients with Rett syndrome and their families.
Advertisement
In-Article Ad
Reader Poll
How important do you think leadership changes are for biotech companies?
Connecting to poll...
Read the original article
Visit the source for the complete story.




